1. CCLHD Research Repositories

Cecily Forsyth

View Statistics Email Alert RSS Feed

Profile

Loading... 2 0 20 0 false
Credit Name
Cecily Forsyth
Full Name
Forsyth, Cecily
Variants
Forsyth, Cecily J
 
Main Affilation
Central Coast Local Health District
 
Department
 
ORCID
Loading... 3 0 20 0 false

Publications

Refined By:
Subject:  Leukaemia

Results 1-9 of 9 (Search time: 0.001 seconds).

PreviewIssue DateTitleAuthor(s)
1Apr-2019The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemiaForsyth, Cecily J ; Minson, A.G.; Cummins, K.; Fox, L.; Costello, B.; Yeung, D.; Cleary, R.; Tatarczuch, M.; Burbury, K.; Motorna, O.; Shortt, J.; Fleming, S.; McQuillan, A.; Schwarer, A.; Harrup, R.; Holmes, A.; Ratnasingam, S.; Chan, K.L.; Hsu, W.H.; Ashraf, A.; Putt, F.; Grigg, A.
2Apr-2018Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic LeukaemiaForsyth, Cecily J ; Crassini, K.R.; Zhang, E.; Balendran, S.; Freeman, J.A.; Best, O.G.; Mackinlay, N.J.; Han, P.; Stevenson, W.S.; Mulligan, S.P.
3May-2017The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemiaForsyth, Cecily J ; Fox, L.; Cummins, K.D.; Costello, B.; Yeung, D.; Cleary, R.; Tatarczuch, M.; Burbury, K.; Motorna, O.; Shortt, J.; Fleming, S.; McQuillan, A.; Schwarer, A.; Harrup, R.; Holmes, A.; Ratnasingam, S.; Chan, K.L.; Hsu, W.H.; Ashraf, A.; Putt, F.; Grigg, A.
4Mar-2017A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosisForsyth, Cecily J ; Ho, P.J.; Bajel, A.; Burbury, K.; Dunlop, L.; Durrant, S.; Perkins, A.C.; Ross, D.M.
5Apr-2016Dysregulation of the intrinsic apoptotic pathway mediates megakaryocytic hyperplasia in myeloproliferative neoplasmsForsyth, Cecily J ; Malherbe, J.A.; Fuller, K.A.; Mirzai, B.; Kavanagh, S.; So, C.C.; Ip, H.W.; Guo, B.B.; Howman, R.; Erber, W.N.
6Feb-2015TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.Yeung, D.; Osborn, M.; White, D.; Branford, S.; Braley, J.; Herschtal, A.; Kornhauser, M.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.L.; Trotman, J.; Forsyth, Cecily J ; Taper, J.; Ross, D.M.; Beresford, J.; Tam, C.; Mills, A.K.; Grigg, A.; Hughes, T.
7May-2014Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyureaForsyth, Cecily J ; Verner, E.; Grigg, A.
8Oct-2001Abnormal dicentric chromosome with co-amplification of sequences from chromosomes 11 and 19: a novel rearrangement in a patient with myelodysplastic syndrome transforming to acute myeloid leukemiaForsyth, Cecily J ; Smith, A.; Heaps, L.S.; Sharma, P.; Jarvis, A.
91995Quantifying the loss of ABO antigenicity in a patient with acute myeloid leukemia by flow cytometric analysisForsyth, Cecily J ; Popp, H.J.; Nelson, M.; Falson, M.; Kronenberg, H.